Compare Repligen Corporation Common Stock (RGEN) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Wipro Limited — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Wipro Limited trades at $1.76 (market cap $17.45B). The key difference: Wipro Limited is the larger of the two by market cap, and Wipro Limited pays a 4.82% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Wipro Limited for 41 Days on average.
| RGEN | WIT | |
|---|---|---|
Market Cap | $11.14B | $17.45B |
Volume | 1,259,263 | 12,096,194 |
Sector | Health | Technology |
52-Week High | $194.57 | $3.06 |
52-Week Low | $102.87 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $11.02B | $15.54B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The company maintains solid fundamentals with $890.88B revenue, 13.92% net margin, and $131.35B net income for 2025. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. However, the stock faces mixed analyst sentiment with only 19% buy ratings and recent earnings misses.
Wipro presents a mixed investment case with reasonable valuation (P/E 13.84) and strong cash flow generation offset by earnings volatility and competitive pressures. The AI transformation offers growth potential, but investors should weigh execution risks against the company's established market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
